Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant
Poolbeg will act as the lead business partner alongside Johnson & Johnson and other partners
8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (“CRS”) research programme.
